HCG
Investigación publicada y base de evidencia
Human chorionic gonadotropin is a heterodimeric placental glycoprotein hormone that shares an alpha subunit with LH, FSH and TSH and signals through the luteinizing hormone/chorionic gonadotropin receptor (LHCGR), reproducing LH activity with a substantially longer circulating half-life. Urinary-derived hCG and recombinant choriogonadotropin alfa are approved agents used to trigger final oocyte maturation and ovulation in assisted reproduction, to support Leydig-cell testosterone production and induce or maintain spermatogenesis in male hypogonadotropic hypogonadism, and historically as hormonal therapy for undescended testis. Serum hCG measurement is also a core diagnostic assay in pregnancy monitoring and in gestational trophoblastic disease. The evidence base is large and dominated by randomised trials and their syntheses, so recent systematic reviews, network meta-analyses and Cochrane reviews carry most of the weight; controlled evidence does not support hCG as a weight-loss agent.
- La HCG es una hormona placentaria que imita la LH con una vida media más larga.
- Ensayos muestran que desencadena la ovulación en reproducción asistida.
- La evidencia no respalda la HCG para pérdida de peso.
40 estudios · 15 desde 2023 · más reciente 2026
- Estudios citados
- 40
- Publicados en 2023+
- 15
- Artículo más reciente
- 2026
- Última revisión
- oct 2026
Temas recurrentes en la literatura
- LH/CG receptor (LHCGR) agonist
- ovulation and final oocyte maturation trigger
- dual trigger (hCG plus GnRH agonist)
- OHSS risk and trigger selection
- luteal phase support
- male hypogonadotropic hypogonadism
- induction of spermatogenesis and fertility restoration
- pubertal induction in males
- cryptorchidism / undescended testis
- intrauterine insemination timing
- hCG assay in pregnancy and gestational trophoblastic disease
- no established role in weight loss
Identificadores del compuesto
40 estudios publicados.
Ordenados por solidez del diseño del estudio, luego por antigüedad. Cada entrada enlaza a su registro fuente para que el hallazgo pueda verificarse contra el artículo en lugar de tomarse bajo nuestra palabra.
- 01Guía clínica2026
Care of Patients with Male Hypogonadism: A Joint Position Statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), the Brazilian Society of Urology (SBU), and the Brazilian Association for Sexual Medicine and Health (ABEMSS).
Hohl A, et al. · Int Braz J Urol · joint position statement of three Brazilian societies (SBEM, SBU, ABEMSS)
The statement recommended testosterone replacement for confirmed organic hypogonadism and listed fertility-preserving strategies, including SERMs, hCG and aromatase inhibitors, when indicated; it also addressed functional hypogonadism related to obesity and anabolic-steroid use.
- 02Revisión sistemática2026
Intrauterine human chorionic gonadotropin administration before embryo transfer (IHABT): an individual participant data meta-analysis of randomized controlled trials
Zou H, et al. · Hum Reprod Update · individual participant data meta-analysis of randomised controlled trials in IVF/ICSI patients
Pooled individual participant data from randomised trials were used to re-examine whether intrauterine instillation of hCG before embryo transfer alters live birth and clinical pregnancy outcomes, an intervention for which earlier aggregate-data syntheses had reported inconsistent effects.
- 03Revisión sistemática2026
Oocyte maturation triggering in high responders in IVF treatment: a systematic review and network meta-analysis
Beebeejaun Y, et al. · Front Endocrinol (Lausanne) · network meta-analysis of randomised trials in high ovarian responders undergoing IVF
Trigger strategies were compared in patients at elevated risk of ovarian hyperstimulation syndrome, with attention to how GnRH agonist and dual-trigger regimens perform relative to conventional hCG trigger on live birth and OHSS incidence.
- 04Revisión sistemática2026
Efficacy of dual triggering in poor ovarian responders defined according to Bologna and POSEIDON criteria: a systematic review with meta-analysis
Mercorio A, et al. · J Assist Reprod Genet · meta-analysis of trials in poor ovarian responders (Bologna / POSEIDON criteria)
Dual trigger combining hCG with a GnRH agonist was compared with hCG trigger alone in poor responders, addressing oocyte yield and maturation endpoints in a subgroup where trigger optimisation has been proposed but is not standardised.
- 05Revisión sistemática2026
Boosting Male Fertility: The Impact of Gonadotropin Therapy on Hypogonadotropic Hypogonadism-A Systematic Review and Meta-Analysis
Huijben M, et al. · Andrology · meta-analysis of gonadotropin therapy studies in men with hypogonadotropic hypogonadism
hCG-based gonadotropin regimens, with or without added FSH, were pooled for effects on testicular volume, sperm appearance in the ejaculate and pregnancy outcomes in men with hypogonadotropic hypogonadism.
- 06Revisión sistemática2025
Triggering oocyte maturation in in vitro fertilization treatment in healthy responders: a systematic review and network meta-analysis
Beebeejaun Y, et al. · Fertil Steril · network meta-analysis of randomised trials in normal (healthy) responders undergoing IVF
Available randomised evidence comparing hCG, recombinant hCG, GnRH agonist and combined triggers in normal responders was ranked, with the analysis reporting limited certainty for differences in live birth between trigger agents.
- 07Revisión sistemática2025
Reproductive outcome after frozen embryo transfer with hormone replacement therapy according to luteal-phase support protocol: systematic review and network meta-analysis of randomized controlled trials
Etrusco A, et al. · Ultrasound Obstet Gynecol · network meta-analysis of randomised trials of luteal phase support in hormone replacement frozen embryo transfer
Luteal-phase support protocols, including regimens incorporating hCG alongside progesterone routes, were compared for live birth and clinical pregnancy after hormone-replacement frozen embryo transfer.
- 08Revisión sistemática2025
Synchronised approach for intrauterine insemination in subfertile couples
Adesina M, et al. · Cochrane Database Syst Rev · Cochrane systematic review of randomised trials of insemination timing in subfertile couples
Methods of synchronising intrauterine insemination with ovulation, including hCG-triggered timing versus detection of the endogenous LH surge, were reviewed; the evidence for a clear advantage of any single timing strategy was judged limited.
- 09Revisión sistemática2025
Efficacy of Gonadotropin Treatment for Induction of Spermatogenesis in Men With Pathologic Gonadotropin Deficiency: A Meta-Analysis
Muir CA, et al. · Clin Endocrinol (Oxf) · meta-analysis of gonadotropin (hCG +/- FSH) treatment in men with pathological gonadotropin deficiency
Rates of spermatogenesis induction with hCG-based therapy were quantified, and predictors of response such as prior pubertal development, baseline testicular volume and cryptorchidism history were examined.
- 10Revisión sistemática2025
Use of Human Chorionic Gonadotropin (HCG) or HCG-Combined Treatments in Male Infertility: A Systematic Review
Shoaib H, Duffy J, Ahmed K · Cureus · systematic review of hCG monotherapy and hCG-combination regimens in male infertility
Reported semen-parameter and hormonal outcomes were summarised across hCG monotherapy and hCG combined with FSH, hMG or selective oestrogen receptor modulators, including use in men with prior exogenous androgen exposure; study designs were heterogeneous and largely non-randomised.
- 11Revisión sistemática2024
Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis
Alexander EC, et al. · Eur J Endocrinol · meta-analysis of gonadotropin regimens for pubertal induction in adolescent and young adult males
Gonadotropin regimens, typically hCG with or without FSH, were assessed against testosterone-only induction for testicular growth and subsequent spermatogenic potential in males with hypogonadotropic hypogonadism.
- 12Revisión sistemática2021
Effect of adjunctive hormonal therapy on testicular descent and spermatogenic function among children with cryptorchidism: a systematic review and meta-analysis
Zhang K, Zhang Y, Chao M · Hormones (Athens) · meta-analysis of hormonal therapy (hCG, GnRH) in children with cryptorchidism
Hormonal therapy produced only modest rates of testicular descent relative to surgery, while its effect on later spermatogenic indices remained uncertain, consistent with guideline positions that discourage routine hormonal treatment of undescended testis.
- 13Revisión sistemática1995
The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis
Lijesen GK, Theeuwen I, Assendelft WJ, Van Der Wal G · Br J Clin Pharmacol · criteria-based meta-analysis of controlled trials of hCG in obesity (Simeons protocol)
Across controlled trials, hCG was not found to be more effective than placebo for weight loss, fat redistribution, hunger or wellbeing when combined with a very-low-calorie diet; the authors concluded there was no scientific evidence supporting hCG in the treatment of obesity.
- 14Clínico humano2026
Gonadotropin therapy in idiopathic hypogonadal non-obstructive azoospermia (APHRODITE Groups 3-4): a multicenter randomized controlled trial
Chandra V, Esteves SC, Sanagoudar S · Front Reprod Health · multicentre randomised controlled trial in men with idiopathic hypogonadal non-obstructive azoospermia
Gonadotropin therapy was randomised in hypogonadal men with non-obstructive azoospermia classified under the APHRODITE criteria, testing whether hormonal stimulation alters sperm retrieval and semen outcomes in a population where treatment has been largely empirical.
- 15Clínico humano2026
Pituitary Axis Impacts and Effectiveness of Clomiphene and Human Chorionic Gonadotropin in Treating Hypogonadism: Cohort Study.
Clift AK, et al. · World J Mens Health · retrospective cohort, n=6,999 men with testosterone deficiency, 6 months
hCG plus testosterone suppressed LH and FSH, clomiphene plus testosterone reduced FSH only, and clomiphene monotherapy raised both; all three strategies achieved physiological total and free testosterone and similar quality-of-life improvements.
- 16Clínico humano2026
The Effect of Intramuscular Human Chorionic Gonadotropin on Endometrial Preparation in Frozen-Thawed Embryo Transfer: A Randomized Clinical Trial.
Moridi M, et al. · Int J Fertil Steril · randomised controlled trial, n=200 infertile women under 40 (188 completed) having cleavage-stage frozen-thawed embryo transfer in hormone-replacement cycles with a GnRH agonist, intramuscular hCG versus no hCG
Implantation, chemical and clinical pregnancy, pregnancy complications, preterm labour and live birth did not differ between groups. Miscarriage per pregnancy was significantly lower with hCG (P=0.011), and per cycle it approached significance (P=0.059).
- 17Clínico humano2021
Intrauterine injection of HCG before embryo transfer: a parallel, double-blind randomized trial.
Abdallah KS, et al. · Reprod Biomed Online · parallel double-blind randomised trial, n=181 women having fresh or vitrified-warmed embryo transfer after IVF, intrauterine hCG versus culture medium before transfer
Live birth was 24% (22/90) with hCG and 19% (17/90) with control (RR 1.29, 95% CI 0.74 to 2.27), not a significant difference, and clinical and ongoing pregnancy also did not differ significantly. The trial was powered only to detect a 20% difference.
- 18Clínico humano2020
GnRH agonist and hCG (dual trigger) versus hCG trigger for final follicular maturation: a double-blinded, randomized controlled study.
Haas J, et al. · Hum Reprod · single-centre double-blind randomised controlled trial, one hundred and fifty-five normal responders having IVF, GnRH agonist plus hCG (dual trigger) versus hCG alone, recruitment stopped after a planned interim analysis
Dual trigger gave more oocytes (13.4 vs 11.1), more mature oocytes and more blastocysts than hCG alone, with higher clinical pregnancy (46.1% vs 24.3%) and live birth per transfer (36.2% vs 22%).
- 19Clínico humano2018
Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism: a short-course randomized study.
Habous M, et al. · BJU Int · randomized three-arm trial, n=282 hypogonadal men wishing to preserve fertility, 3 months
Clomiphene, hCG and their combination raised serum testosterone to a similar degree (223% mean increase overall); symptom scores improved in all arms, with greater improvement in the combination arm.
- 20Clínico humano2017
A randomized double-blinded controlled trial of hCG as luteal phase support in natural cycle frozen embryo transfer.
Lee VCY, et al. · Hum Reprod · randomised double-blind placebo-controlled trial, n=450 women with regular cycles having natural-cycle frozen embryo transfer, hCG versus saline as luteal phase support
Ongoing pregnancy (26.7% vs 31.3%), implantation and miscarriage rates did not differ between hCG and saline. Serum oestradiol 6 days after transfer was higher with hCG, while progesterone was similar.
- 21Clínico humano2016
Late-onset hypogonadism: the advantages of treatment with human chorionic gonadotropin rather than testosterone.
La Vignera S, et al. · Aging Male · comparative study (indexed in PubMed as a randomised controlled trial), n=40 men with late-onset hypogonadism, extractive urinary hCG versus three testosterone formulations (10 per group), 6 months
Compared with the testosterone groups, men given hCG had higher 25-OH-vitamin D and lower oestrogens, haematocrit, PSA and prostate volume. Sperm density and progressive motility fell significantly in all testosterone groups compared with the hCG group.
- 22Clínico humano2015
The Use of HCG-Based Combination Therapy for Recovery of Spermatogenesis after Testosterone Use.
Wenker EP, et al. · J Sex Med · retrospective case series, n=49 men with testosterone-associated azoospermia or severe oligospermia
With hCG-based combination therapy, spermatogenesis returned or sperm counts improved in 47 of 49 men (95.9%), with a mean time to recovery of 4.6 months; no man stopped treatment because of adverse events.
- 23Clínico humano2015
Sequential Versus Continual Purified Urinary FSH/hCG in Men With Idiopathic Hypogonadotropic Hypogonadism.
Zhang M, et al. · J Clin Endocrinol Metab · multicentre open-label randomised noninferiority trial, n=67 Chinese men with idiopathic hypogonadotropic hypogonadism, hCG with continual versus sequential urinary FSH, 18 months
A sperm concentration of at least 1.0 million/mL was reached by 51.5% (17/33) with continual FSH plus hCG and 55.9% (19/34) with sequential FSH plus hCG, meeting the noninferiority criterion.
- 24Clínico humano2012
Spontaneous triggering of ovulation versus HCG administration in patients undergoing IUI: a prospective randomized study.
Kyrou D, et al. · Reprod Biomed Online · prospective randomised study, n=300 women having intrauterine insemination in natural cycles, hCG-triggered ovulation versus insemination timed to the spontaneous LH rise
Ongoing pregnancy was significantly lower with hCG triggering (16/150) than with spontaneous LH timing (34/150), although the follicular phase was shorter with hCG.
- 25Clínico humano2011
Intrauterine injection of human chorionic gonadotropin before embryo transfer significantly improves the implantation and pregnancy rates in in vitro fertilization/intracytoplasmic sperm injection: a prospective randomized study.
Mansour R, et al. · Fertil Steril · prospective randomised study in two phases, women under 40 having first IVF/ICSI, intrauterine hCG before embryo transfer at three doses versus no hCG (167 vs 93, then 107 vs 105)
At the two lower doses, implantation and pregnancy rates did not differ from controls. At the highest dose, implantation (41.6% vs 29.5%) and clinical pregnancy (75% vs 60%) were significantly higher than in controls.
- 26Clínico humano2010
Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency.
Roth MY, et al. · J Clin Endocrinol Metab · randomised trial, n=37 healthy men with gonadotropin deficiency induced by a GnRH antagonist, very low hCG doses or no hCG versus testosterone gel, 10 days
Intratesticular testosterone rose in a dose-dependent manner across the very low hCG doses, and serum hCG correlated with both intratesticular and serum testosterone. Doses far lower than those used clinically raised intratesticular testosterone.
- 27Clínico humano2008
The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L, et al. · Fertil Steril · randomised controlled trial, sixty-six high-risk women under 40 having IVF (polycystic ovary syndrome, polycystic ovarian morphology or previous high response), GnRH agonist trigger after antagonist co-treatment versus hCG trigger after agonist down-regulation
No woman in the GnRH agonist trigger group developed OHSS, compared with 31% (10/32) in the hCG trigger group. Implantation (36.0% vs 31.0%), clinical pregnancy and ongoing pregnancy rates did not differ significantly.
Hallazgo de seguridad reportado. Ovarian hyperstimulation syndrome developed in 10 of 32 high-risk women (31%) given an hCG trigger, versus none after a GnRH agonist trigger.
- 28Clínico humano2005
Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression.
Coviello AD, et al. · J Clin Endocrinol Metab · randomized placebo-controlled trial, n=29 healthy men, 3 weeks of testosterone-induced gonadotropin suppression
Exogenous testosterone suppressed LH and FSH to 5% and 3% of baseline and intratesticular testosterone by 94% with placebo; added hCG increased intratesticular testosterone in a dose-dependent manner and maintained it within the normal range.
- 29Clínico humano2005
A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
Kolibianakis EM, et al. · Hum Reprod · randomised controlled trial stopped early, n=106 women having IVF with a GnRH antagonist protocol, urinary hCG versus GnRH agonist (triptorelin) to trigger final oocyte maturation
Oocyte numbers, oocyte maturity, fertilisation and embryo quality did not differ between triggers, but ongoing pregnancy was significantly less likely with the GnRH agonist than with hCG (odds ratio 0.11), and the trial was stopped under its preset stopping rules.
- 30Clínico humano2004
Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency.
Meier C, et al. · J Clin Endocrinol Metab · double-blind placebo-controlled randomised trial, n=40 community-dwelling older men with partial androgen deficiency, subcutaneous recombinant hCG (n=20) versus placebo, 3 months (reported together with a parallel dihydrotestosterone trial)
Recombinant hCG raised serum testosterone and estradiol, the latter to supraphysiological levels, and increased the bone-formation marker S-PINP (peak about 40% at 1 month versus placebo) without changing osteocalcin or bone-resorption markers.
- 31Clínico humano2000
Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment--recombinant HCG versus urinary HCG. The European Recombinant Human Chorionic Gonadotrophin Study Group.
· Hum Reprod · multicentre double-blind double-dummy randomised trial, n=190 women having ovulation induction for assisted reproduction, recombinant hCG (Ovidrel) versus urinary hCG for final follicular maturation
Mean oocytes retrieved did not differ (11.6 vs 10.6), but mature oocytes were higher with recombinant hCG (9.4 vs 7.1). Clinical pregnancy (33% vs 25%) and live birth (27% vs 23%) did not differ significantly, and adverse events (45.1% vs 22.7%) and injection-site reactions were more frequent with urinary hCG.
- 32Clínico humano1994
Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.
Araujo E, et al. · J Assist Reprod Genet · prospective randomised comparison, n=77 women having IVF after GnRH agonist and controlled ovarian hyperstimulation, subcutaneous hCG (n=38) versus intramuscular progesterone (n=39) for luteal-phase support
Clinical pregnancy (36.7% vs 35.3%) and implantation rates were similar. Five of 38 women given hCG developed moderate to severe OHSS soon after the first or second supplementary hCG injection, while 6 of 39 given progesterone had injection-site allergic reactions.
Hallazgo de seguridad reportado. Moderate to severe ovarian hyperstimulation syndrome developed in 5 of 38 women after luteal-phase hCG injections.
- 33Clínico humano1992
Hormonal treatment of cryptorchidism--hCG or GnRH--a multicentre study.
Christiansen P, et al. · Acta Paediatr · modified double-blind controlled multicentre study, 163 prepubertal boys with bilateral and 94 with unilateral cryptorchidism, intramuscular hCG versus intranasal GnRH or placebo
hCG produced complete descent of both testes in 23% of boys with bilateral cryptorchidism and complete descent in 19% with unilateral cryptorchidism, significantly better than GnRH or placebo. All treatments were more successful in younger boys.
- 34Clínico humano1992
Human chorionic gonadotrophin (hCG) in the management of recurrent abortion; results of a multi-centre placebo-controlled study.
Harrison RF · Eur J Obstet Gynecol Reprod Biol · international ten-centre double-blind placebo-controlled trial, seventy-five pregnant women with habitual (recurrent) abortion who completed the trial, intramuscular hCG versus placebo in early pregnancy
83% of pregnancies on hCG were successful compared with 79% on placebo (P = 0.45), with similar results in women with no identified cause, and no differences in delivery weight, placental weight or Apgar score.
- 35Clínico humano1990
Human chorionic gonadotrophin and weight loss. A double-blind, placebo-controlled trial.
Bosch B, et al. · S Afr Med J · double-blind placebo-controlled trial, forty obese women (body mass index above 30) on the same restricted diet, intramuscular hCG versus saline injections, 6 weeks
Women given hCG showed no advantage over placebo in weight loss, hunger, body circumferences, psychological profile or fasting blood measures.
- 36Clínico humano1986
Hormonal therapy of cryptorchidism. A randomized, double-blind study comparing human chorionic gonadotropin and gonadotropin-releasing hormone.
Rajfer J, et al. · N Engl J Med · randomised double-blind comparison, n=33 boys aged one to five years with cryptorchidism, parenteral hCG versus intranasal GnRH, four weeks
Testicular descent occurred in 1 of 17 boys (6%) given hCG and 3 of 16 (19%) given GnRH, not a significant difference, although hCG produced higher testosterone levels. In a separate uncontrolled group of five boys with retractile testes, hCG brought every testis into the scrotum.
- 37Clínico humano1976
Chorionic gonadotropin in weight control. A double-blind crossover study.
Young RL, et al. · JAMA · double-blind randomised crossover study, two hundred two patients in a weight-reduction programme, hCG versus placebo injections
There was no statistically significant difference between hCG and placebo in weight, skin-fold thickness, dropout or subjective response during any phase of the study.
- 38Clínico humano1976
Ineffectiveness of human chorionic gonadotropin in weight reduction: a double-blind study.
Stein MR, et al. · Am J Clin Nutr · prospective randomised double-blind comparison, fifty-one obese women aged 18 to 60 on the same very-low-calorie diet, hCG versus placebo injections, 32 days
Weight loss, percentage weight loss, hip and waist circumference and hunger ratings did not differ significantly between hCG and placebo; twenty of 25 in the hCG group and 21 of 26 in the placebo group completed the injections. The trial repeated the design of the 1973 Asher-Harper study, which had reported a benefit.
- 39Animal in vivo2026
Luteinizing hormone receptor knockout mouse: What has it taught us?
Huhtaniemi IT · Andrology · review of LHCGR-null (LuRKO) mouse models
Findings from LH/CG receptor knockout mice were synthesised, indicating that LHCGR signalling is dispensable for fetal sexual differentiation initiation but required for postnatal Leydig cell maturation, androgen production and completion of gametogenesis, delineating the receptor pathway through which hCG acts.
- 40In vitro1994
Crystal structure of human chorionic gonadotropin
Lapthorn AJ, et al. · Nature · X-ray crystallography of deglycosylated human chorionic gonadotropin heterodimer
The alpha and beta subunits were shown to adopt a cystine-knot fold related to that of other growth factors, with the subunits associated in an antiparallel arrangement stabilised by a beta-subunit 'seatbelt' segment, establishing the structural basis for glycoprotein hormone assembly and receptor specificity.
Lo que esta evidencia no establece.
Comparative evidence remains inconclusive on whether any single trigger agent (hCG, GnRH agonist or dual trigger) improves live birth rather than intermediate oocyte endpoints, and adjunctive uses such as intrauterine hCG instillation and hCG-containing luteal support are supported mainly by small, heterogeneous trials. In men, most data on hCG for spermatogenesis induction come from uncontrolled cohorts in congenital or acquired gonadotropin deficiency, with little randomised evidence for hCG used to preserve or restore fertility during or after exogenous androgen exposure, and no controlled support for hCG in weight management.
Preguntas comunes sobre la investigación.
- What is HCG?
Human chorionic gonadotropin is a glycoprotein hormone composed of an alpha subunit shared with LH, FSH and TSH plus a hormone-specific beta subunit. It binds the same receptor as luteinising hormone but persists far longer in circulation, which is why research literature treats it as a long-acting LH surrogate.
- How does it differ from HMG?
HCG supplies LH-like activity only. HMG supplies both FSH and LH activity in roughly equal international units. Published male protocols frequently combine the two precisely because hCG on its own does not provide an FSH signal.
- Is there controlled evidence for hCG in weight loss?
No. A criteria-based meta-analysis of controlled trials of the Simeons protocol, published in 1995, found that hCG was not more effective than placebo for weight loss, fat redistribution, hunger or wellbeing when combined with a very-low-calorie diet. The compound's established evidence base concerns triggering final oocyte maturation and ovulation in assisted reproduction, luteal phase support, and Leydig-cell and spermatogenesis endpoints in male hypogonadotropic hypogonadism.
Disponible en nuestro catálogo
Solo para fines de investigación. No apto para consumo humano, diagnóstico, tratamiento o prevención de ninguna condición. Nada en esta página constituye consejo médico, y ningún estudio resumido aquí debe leerse como una recomendación.